Capital Counsel LLC Has Lowered Its Position in Idexx Labs INC Com (IDXX) by $3.39 Million as Stock Value Rose

September 17, 2017 - By Clifton Ray

Investors sentiment decreased to 0.93 in Q4 2016. Its down 0.21, from 1.14 in 2016Q3. It dropped, as 29 investors sold IDXX shares while 183 reduced holdings. 67 funds opened positions while 130 raised stakes. 75.18 million shares or 3.36% less from 77.79 million shares in 2016Q3 were reported. Nebraska-based Farmers Merchants Incorporated has invested 0% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Jefferies Ltd Liability accumulated 5,730 shares or 0% of the stock. Henderson Grp Inc Public Limited Company owns 0.18% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 211,737 shares. Sei Invs stated it has 0.01% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Moreover, Blackrock Fund Advsr has 0.08% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Voloridge Inv Mngmt Limited Co has 0.17% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Cap Fund Management Sa reported 2,200 shares stake. Bank & Trust Of Mellon owns 1.04 million shares or 0.04% of their US portfolio. Capital Service Of America Inc reported 100,269 shares stake. First Manhattan Com holds 4,050 shares. 25,761 are owned by Keybank Natl Association Oh. The Delaware-based Reliance Of Delaware has invested 0.04% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Wesbanco Bancshares holds 2,081 shares. Seaward Management Partnership invested in 0.1% or 16,630 shares. Matarin Capital Mngmt Ltd stated it has 15,680 shares.

Since May 3, 2017, it had 0 insider purchases, and 5 selling transactions for $10.08 million activity. Another trade for 1,700 shares valued at $271,912 was sold by HENDERSON REBECCA M. The insider AYERS JONATHAN W sold $4.18M. TWIGGE GIOVANI had sold 2,572 shares worth $429,272. The insider END WILLIAM T sold $812,769.

Capital Counsel Llc decreased its stake in Idexx Labs Inc Com (IDXX) by 3.55% based on its latest 2016Q4 regulatory filing with the SEC. Capital Counsel Llc sold 28,982 shares as the company’s stock rose 13.64% with the market. The institutional investor held 786,956 shares of the health care company at the end of 2016Q4, valued at $92.29 million, down from 815,938 at the end of the previous reported quarter. Capital Counsel Llc who had been investing in Idexx Labs Inc Com for a number of months, seems to be less bullish one the $13.87B market cap company. The stock increased 0.11% or $0.17 on September 15, reaching $158.97. About 774,056 shares traded or 47.14% up from the average. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 83.30% since September 17, 2016 and is uptrending. It has outperformed by 66.60% the S&P500.

Analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report $0.75 EPS on November, 7.They anticipate $0.13 EPS change or 20.97 % from last quarter’s $0.62 EPS. IDXX’s profit would be $65.44 million giving it 52.99 P/E if the $0.75 EPS is correct. After having $0.95 EPS previously, IDEXX Laboratories, Inc.’s analysts see -21.05 % EPS growth.

More recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Finance.Yahoo.com which released: “IDEXX Laboratories (IDXX), Great Growth Pick: Here’s Why” on August 25, 2017. Also Benzinga.com published the news titled: “IDEXX Labs Is ‘Top Dog'” on August 24, 2017. Nasdaq.com‘s news article titled: “Zacks.com featured highlights include Lululemon Athletica, Sanderson Farms …” with publication date: September 12, 2017 was also an interesting one.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Ratings Coverage

Among 9 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 5 have Buy rating, 2 Sell and 2 Hold. Therefore 56% are positive. IDEXX Laboratories has $185.0 highest and $69.50 lowest target. $119.08’s average target is -25.09% below currents $158.97 stock price. IDEXX Laboratories had 20 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, July 20. The rating was maintained by Stifel Nicolaus on Thursday, August 13 with “Buy”. The firm has “Market Perform” rating by Raymond James given on Friday, August 28. Credit Suisse maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) rating on Wednesday, April 13. Credit Suisse has “Outperform” rating and $85 target. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Buy” rating by Stifel Nicolaus on Monday, August 21. The company was reinitiated on Thursday, September 29 by Bank of America. As per Friday, July 28, the company rating was upgraded by C.L. King. The firm earned “Buy” rating on Monday, March 21 by Stifel Nicolaus. As per Thursday, October 29, the company rating was maintained by Stifel Nicolaus. The firm has “Buy” rating given on Tuesday, June 13 by Canaccord Genuity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.